2 Under-the-Radar Biotech Stocks to Buy in 2022
A series of regulatory setbacks led to Axsome Therapeutics' slump over the past year, but the biotech is on the rebound. Axsome's AXS-05, a potential therapy for major depressive disorder, failed to make it past its last regulatory hurdle in August 2021 -- that is, marketing approval from the U.S. Food and Drug Administration (FDA).